PekCura Labs FDA Warning Letter: Letter 721709

Updated August 23, 2026

PekCura Labs of Pensacola, Florida is the recipient of FDA warning letter 721709, dated March 31, 2026 and posted April 7, 2026 — one of seven letters to research-peptide sellers in a single-day action. This page records the batch's documented findings and where the letter can be retrieved.

The two documented findings

The seven letters of March 31, 2026 rest on two categories of evidence, per the batch and contemporaneous regulatory coverage. First: product-page text carrying therapeutic-effect descriptions of compounds sold under research-use labels. Second: the composition of the shopping cart — administration supplies listed for purchase together with the compounds. The letters count the second as evidence in its own right; the cart's contents, not any written sentence, established the point.

FDA on research-use disclaimers

The letters address research-use-only disclaimers head-on rather than around them. The agency's quoted position from the batch: despite the disclaimers, "evidence obtained from your website establishes that your products are intended to be drugs for human use."

Letter record

Retrieving letter 721709

This index links FDA letter pages only where it has confirmed the address, and for the PekCura Labs letter no direct URL has been confirmed — so none is printed and none is guessed. The letter is retrievable through FDA's warning-letters database, linked under Sources, by searching the recipient name or the number 721709.

Coded designations in the batch

The batch record also preserves a naming finding: compounds listed under codes in place of standard nomenclature, with "GLP-1 SM" and "GLP-3 RT" as the documented examples. FDA, per the letters, read the codes as circumvention. Both examples belong to the batch as a whole; this index does not attribute them to PekCura Labs or to any single recipient.

The rest of the batch

PekCura Labs is one of two Florida recipients in the action; the other five letters went to sellers in Colorado, Arizona, California, Michigan, and Illinois. All seven letter numbers, entities, and locations are tabulated at the April 2026 batch record, and each recipient is held in the vendor index.

How the letter is numbered

Warning letters in this batch pair a number with the letter date: where this index has confirmed an FDA page address for a recipient, that address ends in the letter number plus the date suffix 03312026. For PekCura Labs no address has been confirmed, so the database search under Sources — by recipient name or by 721709 — is the citation this index stands behind.

Outside this record

No response deadline is captured here for the March 2026 batch, and nothing in this index documents PekCura Labs' actions after the letter date. The record on this page begins and ends with the letter itself.

Sources

1. FDA Warning Letters index (PekCura Labs, letter 721709). fda.gov
2. Policy Canary analysis of the batch. policycanary.io
3. Partnership for Safe Medicines, PDF summary of the seven letters (posted April 7, 2026). safemedicines.org

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.